Defunct Company
Total Trials
6
As Lead Sponsor
As Collaborator
0
Total Enrollment
306
NCT01504542
Immune Response and Safety of HS110 Vaccine in Combination With Erlotinib in Patients With Non-Small Cell Lung Cancer
Phase: Phase 2
Role: Lead Sponsor
Start: Dec 31, 2011
Completion: Dec 31, 2013
NCT02010203
A Phase 1/2 Study of HS-410 in Patients With Non-Muscle Invasive Bladder Cancer After TURBT
Phase: Phase 1/2
Start: Dec 31, 2013
Completion: Apr 30, 2018
NCT02117024
A Phase 2 Study of Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer
Start: Jul 31, 2014
NCT02439450
A Study of Combination Therapies With Viagenpumatucel-L (HS-110) in Patients With Non-Small Cell Lung Cancer
Start: Apr 15, 2015
Completion: Nov 4, 2022
NCT04116710
A Phase 1 Study of HS130 in Combination With Viagenpumatucel-L (HS110) in Patients With Solid Tumors
Phase: Phase 1
Start: Oct 18, 2019
Completion: Apr 1, 2022
NCT05116969
A Phase 1 Study of PTX-35 in Healthy Volunteers
Start: Nov 24, 2021
Completion: Nov 29, 2022